Category: Uncategorized

18
Jul

OncoCell MDx Appoints Renowned Urologic Pathologist as Chief Medical Officer

ROYAL OAK, Mich., — July 18, 2019 — OncoCell MDx, an immunogenomics platform company specializing in the delivery of novel, noninvasive molecular diagnostic assays, today announced that Kirk Wojno, M.D., has joined the company’s leadership team as its Chief Medical Officer. Dr. Wojno, a renowned urologic pathologist and expert in prostate biopsy interpretation, joins an expanding, experienced executive team. OncoCell MDx also recently announced the appointments of Mark McDonough as President and CEO and Christopher Thibodeau as Chief Operating Officer.

“OncoCell is in an exciting phase of growth. We are moving toward commercialization of our first immunogenomics test for prostate cancer, and we are continuing to develop our pipeline of noninvasive tests for other cancers and diseases,” said McDonough. “Dr. Wojno brings a wealth of knowledge of the company and the space, an illustrious reputation, expert knowledge of anatomic and molecular pathology, and deep experience running clinical affairs and laboratory operations. I’m really pleased to work with him, with Christopher and with the rest of the OncoCell team to drive transformational advances in patient care.”

Dr. Wojno is a nationally renowned pathology expert in prostate cancer. He is the former head of Urologic Pathology at the University of Michigan, at Ascension Health System, and at national Ameripath Laboratories. He has more than 30 years in medical practice and most recently served as the Chief of Pathology and Laboratory Services and Director of Clinical Research for Comprehensive Urology located in Royal Oak, Michigan, one of the largest urology group practices in the United States. While at Johns Hopkins University, Dr. Wojno trained with the Brady Institute’s Jonathan Epstein, M.D. an internationally recognized authority in uropathology. Dr. Wojno received his medical degree from Wayne State University School of Medicine.

“Screening, diagnosis and management of prostate cancer continues to be challenging due to tumor heterogeneity and complexity,” said Kirk Wojno, M.D. “As a practicing pathologist over the past three decades, I’m delighted to work with OncoCell in addressing a significant need to improve patient selection for active surveillance and to provide a noninvasive method for annual monitoring. Our goal is to help reduce overtreatment of indolent disease along with patient anxiety. I am equally excited about the promise this technology offers across a broad spectrum of diagnostic indications, from cancer, cardiovascular, infectious and neurodegenerative disease, to immune- and kidney-related diseases.”

About OncoCell MDx:

OncoCell MDx is a privately held company developing and commercializing novel diagnostic tests utilizing proprietary technologies created at Harvard Medical School by OncoCell MDx’s founder, Professor Amin I. Kassis. The company’s noninvasive blood-based immunogenomic assays are designed to aid physicians to better understand underlying disease pathology in prostate cancer and other oncology and non-oncology indications. For more information about OncoCell MDx and its technology, visit: https://oncocellmdx.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190718005153/en/OncoCell-MDx-Appoints-Renowned-Urologic-Pathologist-Chief

Contact:
Virginia Amann for OncoCell MDx
VirginiaAmann@ENTENTEInc.com
M: +1.608.207.0082 (preferred)

O: +1.312.416.8438

###

02
Apr

OncoCell Announces Late-Breaking Poster Presentation at AACR 2019 on a Noninvasive Blood-Based Assay for Prostate Cancer Prognosis

April 1, 2019 – ATLANTA – OncoCell MDx, a company developing novel noninvasive diagnostic and prognostic tests, will present results from a feasibility study of a new prostate cancer prognostic assay in a late-breaking poster session at the American Association of Cancer Research (AACR) Annual Meeting tomorrow. The study demonstrates that the blood-based immunogenomics RNA expression assay provides a prognostic summary comparable to that of prostate biopsy.

OncoCell’s Subtraction-Normalized Expression of Phagocytes (SNEP) based platform, invented by Professor Amin Kassis, while at Harvard Medical School, uses a proprietary algorithm to interrogate changes in gene expression of two immune cell types consequent to prostate cancer including phagocytic (CD14) and non-phagocytic (CD2) cells, filters out intrinsic genomic variation not related to the disease, and identifies and validates prostate cancer-specific signatures. A study of blood samples from 713 prostate cancer patients showed the platform provides a prognostic summary including tumor Gleason grade distribution, size/volume and heterogeneity that is comparable to prostate biopsy information, and that it stratifies patients with aggressive disease that need life-saving treatment from those with indolent disease.

In the study, CD2 and CD14 cells were isolated from peripheral blood samples and mRNA samples were extracted and sequenced from each cell type. Transcripts with quantifiable expression changes were used to train OncoCell’s proprietary SNEP-based algorithm to stratify the patients into those who need treatment versus surveillance. A genomic signature was identified that is predictive of Gleason grade, cores positive and maximum involvement. Signature scores were significantly associated with these endpoints and an Aggressiveness Index that incorporates the three endpoints. Samples from two independent sets of naïve patients (n=305 and n=470) validated the results.

“We are encouraged by the results of these study findings, which suggest this assay may play an important role in advancing clinical management of prostate cancer patients,” said Philip Kantoff, M.D., Clinical Advisor to OncoCell and Chair of the Department of Medicine, Memorial Sloan Kettering Cancer Center.

Details of the study are being presented April 2 from 1:00 p.m. to 5:00 p.m. EDT in a poster session titled “Immuno-genomic detection and prognostication of aggressive prostate cancer phonotypes by next-generation RNA sequencing” (https://www.abstractsonline.com/pp8/#!/6812/presentation/9127)at theGeorgia World Congress Center, Exhibit Hall B, Poster Section 41, Poster Board Number 19.

The poster will be made available on the company’s website at www.oncocellmdx.com.

About OncoCell MDx

OncoCell MDx is a privately held company developing and commercializing novel diagnostic tests utilizing proprietary technologies created at Harvard Medical School.  The company’s noninvasive blood-based immunogenomic assays are designed to aid physicians to better understand underlying disease pathology in prostate cancer and other oncology and non-oncology indications.

Press Contact:
Virginia Amann for OncoCell MDx
VirginiaAmann@ENTENTEInc.com
+1.608.207.0082